SGK

SGK
Name	Serum- and Glucocorticoid-Regulated Kinase (SGK)
Family	AGC kinase
Organism	Homo sapiens
Length	~431 aa (isoform-dependent)
Gene	SGK1, SGK2, SGK3
Location	Cytoplasm, nucleus, endosomes

SGK is a family of serine/threonine protein kinases regulated by hormonal and stress signals and related to the AGC kinase subfamily. Members include SGK1, SGK2, and SGK3, which integrate inputs from insulin, glucocorticoid receptor, phosphoinositide 3-kinase, and mTOR pathways to modulate ion transporters, channels, and transcription factors. SGK proteins are implicated in cellular survival, proliferation, and ion homeostasis, and have been studied in contexts ranging from renal physiology to cancer and neurodegeneration.

Overview

SGK kinases were first characterized in studies involving glucocorticoid receptor signaling, insulin-like growth factor 1 receptor activation, and osmotic stress responses in mammalian tissues such as the kidney, brain, and heart. SGK1 expression is rapidly induced by glucocorticoids and serum, while SGK2 and SGK3 exhibit distinct expression patterns regulated by androgen receptor and growth factor signaling. SGKs phosphorylate substrates shared with protein kinase B (AKT1), including members of the forkhead box O family and the E3 ubiquitin ligase NEDD4-2, affecting proteins like ENaC, ROMK2, and CFTR.

Gene and Protein Structure

SGK1, SGK2, and SGK3 genes map to human chromosomes studied alongside loci such as NR3C1 and PIK3CA; their transcripts undergo alternative splicing similar to patterns seen in TP53 and EGFR. SGK proteins contain an N-terminal catalytic domain homologous to PKA, PKC, and AKT1, a regulatory hydrophobic motif targeted by mTORC2 and phosphoinositide-dependent kinases, and variable N-terminal regions that determine subcellular targeting akin to differences observed between SRC family kinases. Crystal structures and homology models reference templates such as PKA catalytic subunit and AKT1 crystal structure for conserved motifs including the activation loop and DFG motif.

Regulation and Activation

Activation requires phosphorylation by upstream kinases including PDK1 at the activation loop and mTORC2 at the hydrophobic motif, reminiscent of regulation of AKT1 and SGK3 interactions with PI3K products. SGK expression is induced by nuclear receptors such as glucocorticoid receptor and mineralocorticoid receptor, and by growth factors signaling through EGFR, IGF1R, and FGFR. SGK proteins are modulated by second messengers like phosphatidylinositol (3,4,5)-trisphosphate as in PI3KCA-driven pathways, and by ubiquitin ligases including NEDD4-2 and deubiquitinases analogous to USP10 regulation observed for other kinases. Post-translational modifications include phosphorylation, ubiquitination, and proteasomal degradation pathways shared with proteins such as MYC and HIF1A.

Biological Functions and Physiological Roles

SGK isoforms regulate renal sodium reabsorption via effects on epithelial sodium channel, interact with potassium channels like ROMK, and influence chloride transport involving CFTR, thereby participating in electrolyte balance related to aldosterone signaling. In the central nervous system, SGK impacts neuronal excitability, synaptic plasticity, and responses to ischemia in models involving NMDA receptor and AMPA receptor trafficking similar to mechanisms described for BDNF and CREB. SGKs modulate cell survival and proliferation through phosphorylation of transcription factors such as FOXO3 and regulators like MDM2, intersecting with oncogenic pathways driven by KRAS, PIK3CA, and PTEN loss. In metabolic tissues, SGK participates in insulin signaling with cross-talk to IRS1, AKT1, and GLUT4 trafficking.

Clinical Significance and Disease Associations

Altered SGK activity is linked to hypertension via effects on sodium handling involving ENaC and aldosterone-responsive pathways, with clinical overlaps to Liddle syndrome and variants in SCNN1A. SGK overexpression or deregulation appears in cancers including prostate cancer, breast cancer, colorectal cancer, lung adenocarcinoma, and glioblastoma, often in tumors with aberrant PI3K/AKT/mTOR signaling or mutations in PTEN and PIK3CA. SGK involvement has been observed in ischemic stroke, epilepsy, diabetic nephropathy, and inflammatory conditions where cytokines like TNF-alpha and IL-6 modify expression. Pharmacological interest includes SGK inhibitors evaluated alongside agents targeting mTOR, PI3K inhibitors, and chemotherapeutics such as cisplatin that elicit survival pathways.

Research Tools and Experimental Studies

Model systems include knockout mice for SGK1 and SGK3, cellular assays in lines such as HEK293, COS-7, and cancer models like MCF-7 and PC3. Techniques used to study SGK comprise kinase assays referencing standards like CK2 and PKA, phospho-specific antibodies analogous to those for AKT1 pS473, CRISPR/Cas9 gene editing paralleling work on BRCA1, and phosphoproteomics workflows used in studies of MAPK1 and CDK1. Small-molecule inhibitors and peptide substrates are assessed in high-throughput screens similar to campaigns against BRAF and EGFR. Clinical biomarker studies correlate SGK expression with outcomes in cohorts characterized by markers such as Ki-67 and p53 status.

Evolution and Comparative Genomics

SGK homologs are conserved across vertebrates and invertebrates with orthologs analyzed in Mus musculus, Danio rerio, Drosophila melanogaster, and Caenorhabditis elegans. Comparative genomics places SGK within the AGC kinase family alongside AKT1, SGK3, PKC-alpha, and SGK2, with evolutionary analyses using phylogenies that include SRC, ABL1, and MAPK3. Sequence conservation of catalytic motifs is traced through databases and comparative studies involving genomes of Homo sapiens, Pan troglodytes, Gallus gallus, and Xenopus laevis.

Category:Protein kinases Category:AGC kinases Category:Signal transduction